ELAN - Elanco Animal Health Inc Stock Price, Fair Value and News

13.58USD+0.17 (+1.27%)Market Closed

Market Summary

USD13.58+0.17

Market Closed

1.27%

ELAN Alerts

2 major insider buys recently.

ELAN Stock Price

View Fullscreen

ELAN RSI Chart

ELAN Valuation

Market Cap

6.7B

Price/Earnings (Trailing)

-5.44

Price/Sales (Trailing)

1.52

EV/EBITDA

-53.92

Price/Free Cashflow

51.1

ELAN Price/Sales (Trailing)

ELAN Profitability

EBT Margin

-27.05%

Return on Equity

-19.78%

Return on Assets

-8.57%

Free Cashflow Yield

1.96%

ELAN Fundamentals

ELAN Revenue

Revenue (TTM)

4.4B

Rev. Growth (Yr)

5.13%

Rev. Growth (Qtr)

-3.09%

ELAN Earnings

Earnings (TTM)

-1.2B

Earnings Growth (Yr)

-161.11%

Earnings Growth (Qtr)

87.14%

Breaking Down ELAN Revenue

Last 7 days

-7.9%

Last 30 days

-13.4%

Last 90 days

-7.0%

Trailing 12 Months

43.6%

How does ELAN drawdown profile look like?

ELAN Financial Health

Current Ratio

2.75

Debt/Equity

0.92

Debt/Cashflow

0.05

ELAN Investor Care

Shares Dilution (1Y)

0.29%

Diluted EPS (TTM)

-2.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.4B	4.3B	4.4B	4.4B
2022	4.7B	4.6B	4.5B	4.4B
2021	3.9B	4.6B	4.8B	4.8B
2020	3.0B	2.8B	2.9B	3.3B
2019	3.1B	3.1B	3.1B	3.1B
2018	2.9B	3.0B	3.0B	3.1B
2017	2.9B	2.9B	2.9B	2.9B
2016	0	0	0	2.9B
2015	0	0	0	2.9B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Elanco Animal Health Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	bettington timothy j	sold (taxes)	-363,484	15.43	-23,557	see remarks
Apr 01, 2024	modi rajeev a.	sold (taxes)	-119,919	15.97	-7,509	see remarks
Mar 08, 2024	doyle william f	bought	244,500	16.3	15,000	-
Mar 08, 2024	harrington michael j	bought	50,493	16.2883	3,100	-
Mar 06, 2024	hoover r david	bought	322,808	16.1404	20,000	-
Mar 05, 2024	young todd s.	gifted	-	-	1,500	see remarks
Mar 05, 2024	young todd s.	gifted	-	-	-37,999	see remarks
Mar 05, 2024	simmons jeffrey n	sold (taxes)	-176,082	15.99	-11,012	president, ceo and director
Mar 05, 2024	young todd s.	gifted	-	-	37,999	see remarks

Which funds bought or sold ELAN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Perpetual Ltd	reduced	-9.86	-373,943	16,835,600	0.16%
Apr 16, 2024	180 WEALTH ADVISORS, LLC	reduced	-10.57	-2,245	404,118	0.07%
Apr 16, 2024	Register Financial Advisors LLC	new	-	15,206	15,206	0.01%
Apr 15, 2024	Sunbelt Securities, Inc.	unchanged	-	22,080	260,480	0.03%
Apr 15, 2024	RMR Wealth Builders	unchanged	-	32,020	377,745	0.05%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	new	-	1,887,210	1,887,210	0.05%
Apr 15, 2024	MCDONALD PARTNERS LLC	new	-	358,160	358,160	0.10%
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	reduced	-26.83	-38.00	1,466	-%
Apr 12, 2024	AdvisorNet Financial, Inc	reduced	-72.44	-1,322	570	-%
Apr 11, 2024	Douglas Lane & Associates, LLC	reduced	-0.45	5,130,280	63,646,000	0.90%

Are Funds Buying or Selling ELAN?

Are funds buying ELAN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ELAN

No. of Funds

ELAN Alerts

2 major insider buys recently.

Unveiling Elanco Animal Health Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	dodge & cox	17.0%	83,980,900	SC 13G/A
Feb 13, 2024	vanguard group inc	10.04%	49,468,637	SC 13G/A
Feb 12, 2024	primecap management co/ca/	10.27%	50,600,324	SC 13G/A
Jan 29, 2024	blackrock inc.	5.6%	27,781,483	SC 13G
Nov 08, 2023	primecap management co/ca/	10.28%	50,629,379	SC 13G/A
Sep 11, 2023	vanguard group inc	10.01%	49,307,638	SC 13G/A
Jun 08, 2023	blackrock inc.	4.9%	24,115,385	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	4.0%	18,846,927	SC 13G/A
Feb 14, 2023	dodge & cox	17.9%	84,775,075	SC 13G/A
Feb 09, 2023	primecap management co/ca/	6.96%	32,983,562	SC 13G/A

Recent SEC filings of Elanco Animal Health Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 08, 2024	3	Insider Trading
Apr 08, 2024	3	Insider Trading
Apr 08, 2024	PRE 14A	PRE 14A
Apr 05, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	8-K	Current Report
Mar 26, 2024	4	Insider Trading

Peers (Alternatives to Elanco Animal Health Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	351.1B	85.2B	-6.70%	-10.33%	9.99	4.12	6.46%	95.94%
MRK	317.1B	60.1B	2.45%	9.70%	868.73	5.27	1.40%	-97.49%
PFE	143.3B	46.5B	-8.14%	-36.93%	-103.22	3.08	42.59%	-114.62%
AMGN	140.8B	28.2B	-3.32%	6.70%	20.96	4.99	7.09%	2.52%
GILD	82.4B	27.1B	-9.93%	-21.39%	14.54	3.04	-0.60%	23.36%
TEVA	14.3B	15.8B	-4.27%	50.53%	-24.85	0.9	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-0.96%	-17.31%	-319.58	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-14.12%	-18.81%	11.17	2.39	49.61%	324.78%
BHC	3.1B	8.8B	-9.85%	14.21%	-5.31	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-13.30%	-10.60%	13.51	2.88	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-9.90%	-28.22%	-3.8	1.8	24.65%	80.36%
TXMD	21.7M	1.3M	-17.90%	-49.05%	-2.11	16.65	-98.14%	-109.18%
ACRX	17.6M	-	-9.57%	32.48%	-0.96	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-30.19%	-94.45%	-0.18	0.13	80.00%	43.08%
ACOR	422.3K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Elanco Animal Health Inc News

Latest updates

Elanco Animal Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-3.1%	1,035	1,068	1,057	1,257	985	1,026	1,175	1,226	1,112	1,131	1,278	1,243	1,140	890	586	658	787	771	782	731	799
Costs and Expenses	-46.3%	1,162	2,165	1,136	1,149	1,074	1,070	1,189	1,151	1,237	1,261	1,515	1,322	1,460	1,099	663	726	792	784	731	686	802
S&GA Expenses	-6.7%	292	313	353	327	302	298	343	323	327	342	385	349	374	278	163	182	186	192	201	181	185
R&D Expenses	-8.1%	79.00	86.00	81.00	81.00	80.00	78.00	82.00	81.00	92.00	94.00	94.00	89.00	115	88.00	59.00	67.00	67.00	70.00	69.00	64.00	61.00
EBITDA Margin	-14.1%	-0.05*	-0.04*	0.19*	0.20*	0.19*	0.18*	0.16*	0.11*	0.08*	0.05*	0.02*	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-6.9%	67.00	72.00	74.00	64.00	62.00	60.00	67.00	52.00	55.00	60.00	60.00	61.00	60.00	48.00	25.00	16.00	19.00	19.00	21.00	21.00	21.00
Income Taxes	1500.0%	14.00	-1.00	18.00	5.00	-35.00	21.00	-4.00	24.00	-15.00	-22.00	-37.00	-13.00	5.00	-74.00	-24.00	-19.00	5.00	-22.50	14.00	13.00	-18.60
Earnings Before Taxes	88.4%	-127	-1,097	-79.00	108	-89.00	-44.00	-14.00	75.00	-120	-130	-243	-77.00	-318	-209	-77.00	-68.00	-4.30	-12.50	50.00	45.00	-2.20
EBT Margin	-2.1%	-0.27*	-0.26*	-0.02*	-0.01*	-0.02*	-0.02*	-0.04*	-0.09*	-0.12*	-0.16*	-0.19*	-	-	-	-	-	-	-	-	-	-
Net Income	87.1%	-141	-1,096	-97.00	103	-54.00	-65.00	-10.00	51.00	-105	-108	-206	-64.00	-322	-135	-53.00	-49.00	-9.50	10.00	36.00	32.00	16.00
Net Income Margin	-6.4%	-0.28*	-0.26*	-0.03*	-0.01*	-0.02*	-0.03*	-0.04*	-0.08*	-0.10*	-0.15*	-0.16*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-23.0%	137	178	41.00	-165	-53.00	163	286	-81.00	157	64.00	132	4.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.1%	14,362	14,344	15,796	15,769	15,491	14,948	15,601	16,251	16,478	16,565	16,833	16,988	17,693	17,237	9,876	9,727	8,986	8,824	8,857	8,747	8,957
Current Assets	-4.4%	3,407	3,565	3,652	3,548	3,279	3,154	3,307	3,194	3,274	3,160	3,431	3,344	3,417	3,281	3,191	3,121	2,373	2,310	2,384	2,278	2,505
Cash Equivalents	-4.6%	352	369	367	318	345	460	507	342	638	453	580	515	506	660	1,391	1,206	345	309	385	272	678
Inventory	2.7%	1,735	1,690	1,690	1,596	1,538	1,340	1,334	1,345	1,371	1,383	1,450	1,424	1,578	1,597	1,065	1,019	1,051	1,069	1,053	1,036	1,004
Net PPE	3.4%	1,026	992	1,007	1,000	999	936	961	987	1,055	1,041	1,033	1,271	1,316	1,243	924	930	955	912	931	930	922
Goodwill	3.9%	5,094	4,902	6,040	6,061	5,993	5,716	5,898	6,116	6,172	6,191	6,239	6,016	6,225	6,435	3,044	3,004	2,990	2,946	2,960	2,933	-
Liabilities	-0.9%	8,139	8,210	8,376	8,289	8,202	8,203	8,348	8,639	8,970	8,883	8,853	8,981	9,217	8,893	3,224	3,066	3,439	3,336	3,591	3,551	3,759
Current Liabilities	-1.9%	1,241	1,265	1,284	1,578	1,702	1,613	1,338	1,307	1,647	1,362	1,990	2,034	2,077	1,871	835	708	819	742	778	708	971
Long Term Debt	-2.3%	5,736	5,870	6,023	5,639	5,448	5,507	6,007	6,073	6,025	6,273	5,542	5,556	5,572	5,587	2,030	2,036	2,331	2,336	2,382	2,437	2,443
LT Debt, Current	-2.6%	38.00	39.00	39.00	381	388	394	56.00	61.00	294	61.00	555	605	555	554	26.00	26.00	25.00	25.00	27.00	29.00	29.00
LT Debt, Non Current	-2.3%	5,736	5,870	6,023	5,639	5,448	5,507	6,007	6,073	6,025	6,273	5,542	5,556	5,572	5,587	2,030	2,036	2,331	2,336	2,382	2,437	2,443
Shareholder's Equity	1.5%	6,223	6,134	7,420	7,480	7,289	6,714	7,125	7,585	7,508	7,682	7,980	8,007	8,457	8,344	6,652	6,661	5,543	5,488	5,266	5,196	5,197
Retained Earnings	-6.6%	-2,288	-2,147	-1,051	-954	-1,057	-972	-923	-901	-979	-852	-748	-538	-477	-154	-19.40	34.00	84.00	94.00	84.00	48.00	16.00
Additional Paid-In Capital	0.2%	8,777	8,763	8,752	8,744	8,738	8,724	8,712	8,699	8,696	8,680	8,663	8,647	8,650	8,620	6,886	6,870	5,636	5,646	5,397	5,399	5,403
Accumulated Depreciation	-	-	-	-	744	723	696	688	670	1,041	1,050	1,054	1,060	1,038	983	942	920	931	909	921	909	879
Shares Outstanding	0.0%	493	493	493	492	474	488	488	488	487	487	487	487	-	-	-	-	-	-	-	-	-
Float	-	-	-	4,900	-	-	-	9,300	-	-	-	16,400	-	-	-	8,600	-	-	-	12,400	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-20.7%	157	198	61.00	-145	13.00	189	312	-62.00	223	89.00	149	22.00	-93.00	-112	160	4.00	126	40.00	50.00	8.00	140
Share Based Compensation	50.0%	15.00	10.00	9.00	12.00	15.00	13.00	17.00	14.00	18.00	17.00	16.00	15.00	16.00	12.00	8.00	11.00	12.00	15.00	14.00	8.00	6.00
Cashflow From Investing	2.8%	-35.00	-36.00	-43.00	-55.00	-76.00	-37.00	-37.00	-29.00	-74.00	-441	-25.00	10.00	-74.00	-4,696	11.00	-20.00	-74.50	-83.00	-46.50	-31.00	-48.10
Cashflow From Financing	11.5%	-139	-157	39.00	174	-84.00	-169	-96.00	-200	44.00	231	-67.00	2.00	-18.00	4,068	7.00	897	-6.40	-48.80	90.00	-339	-362

ELAN Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 4,417,000,000	$ 4,411,000,000	$ 4,764,000,000
Costs, expenses and other:
Cost of sales	1,931,000,000	1,913,000,000	2,132,000,000
Research and development	327,000,000	321,000,000	369,000,000
Marketing, selling and administrative	1,285,000,000	1,265,000,000	1,403,000,000
Amortization of intangible assets	548,000,000	528,000,000	556,000,000
Asset impairment, restructuring and other special charges	127,000,000	183,000,000	634,000,000
Goodwill impairment	1,042,000,000	0	0
Interest expense, net of capitalized interest	277,000,000	241,000,000	236,000,000
Other expense, net	75,000,000	32,000,000	5,000,000
Costs, expenses and other	5,612,000,000	4,483,000,000	5,335,000,000
Loss before income taxes	(1,195,000,000)	(72,000,000)	(571,000,000)
Income tax expense (benefit)	36,000,000	6,000,000	(88,000,000)
Net loss	$ (1,231,000,000)	$ (78,000,000)	$ (483,000,000)
Loss per share:
Basic (usd per share)	$ (2.50)	$ (0.16)	$ (0.99)
Diluted (usd per share)	$ (2.50)	$ (0.16)	$ (0.99)
Weighted-average shares outstanding:
Basic (in shares)	492.3	488.3	487.2
Diluted (in shares)	492.3	488.3	487.2

ELAN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 352	$ 345
Accounts receivable, net	842	797
Other receivables	168	205
Inventories	1,735	1,538
Prepaid expenses and other	310	394
Total current assets	3,407	3,279
Noncurrent Assets
Goodwill	5,094	5,993
Other intangibles, net	4,494	4,842
Other noncurrent assets	341	378
Property and equipment, net	1,026	999
Total assets	14,362	15,491
Current Liabilities
Accounts payable	270	390
Employee compensation	157	146
Sales rebates and discounts	367	324
Current portion of long-term debt	38	388
Other current liabilities	409	454
Total current liabilities	1,241	1,702
Noncurrent Liabilities
Long-term debt	5,736	5,448
Accrued retirement benefits	184	161
Deferred taxes	567	662
Other noncurrent liabilities	411	229
Total liabilities	8,139	8,202
Commitments and Contingencies
Equity
Common stock, 5,000,000,000 shares authorized, no par value; 492,845,216 and 474,237,738 shares issued and outstanding as of December 31, 2023 and 2022, respectively	0	0
Additional paid-in capital	8,777	8,738
Accumulated deficit	(2,288)	(1,057)
Accumulated other comprehensive loss	(266)	(392)
Total equity	6,223	7,289
Total liabilities and equity	$ 14,362	$ 15,491

About Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana.

CEO	Mr. Jeffrey N. Simmons
WEBSITE	elanco.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	9000

Elanco Animal Health Inc Frequently Asked Questions

What is the ticker symbol for Elanco Animal Health Inc? What does ELAN stand for in stocks?

ELAN is the stock ticker symbol of Elanco Animal Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Elanco Animal Health Inc (ELAN)?

As of Thu Apr 18 2024, market cap of Elanco Animal Health Inc is 6.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELAN stock?

You can check ELAN's fair value in chart for subscribers.

What is the fair value of ELAN stock?

You can check ELAN's fair value in chart for subscribers. The fair value of Elanco Animal Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Elanco Animal Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ELAN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Elanco Animal Health Inc a good stock to buy?

The fair value guage provides a quick view whether ELAN is over valued or under valued. Whether Elanco Animal Health Inc is cheap or expensive depends on the assumptions which impact Elanco Animal Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELAN.

What is Elanco Animal Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, ELAN's PE ratio (Price to Earnings) is -5.44 and Price to Sales (PS) ratio is 1.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELAN PE ratio will change depending on the future growth rate expectations of investors.